EPALINGES

Industry Leader Greg Roche Joins Distalmotion as CEO

Retrieved on: 
Thursday, December 7, 2023
Roche, Medtech, Zimmer Biomet, Robotics, 3D printing

Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.

Key Points: 
  • Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion , a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO.
  • Roche joins Distalmotion with more than 20 years of commercial and executive experience in the Medtech industry, bringing a wealth of expertise across laparoscopic surgery, endoscopic visualization, and surgical robotics.
  • Most recently, Roche served as CEO of avateramedical, adding to his leadership and experience within soft-tissue robotic technologies.
  • “I am thrilled to join Distalmotion – we have an incredible and talented team that has positioned Distalmotion to become a leader in the next generation of surgical robotics.

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023
DLBCL, The Year's Best Science Fiction: Eleventh Annual Collection, MD Anderson Cancer Center, FDA, NSCLC, NYSE, PIN, University, IHC, S&M, EST, CD22, G&A, Mitsubishi Tanabe Pharma, Society, ASH, Environment, SOHO, Growth, ADC, Clinical trial, Follicular lymphoma, KAAG1, Rituximab, Pancreatic cancer, Lung cancer, Safety, Therapy, American Society of Pediatric Hematology/Oncology, Patient, Immunohistochemistry, AXL, Sarcoma, Bank, Pharmaceutical industry, Video game, Fine chemical, Camisole

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • Net product revenues were $14.3 million for the quarter ended September 30, 2023, compared to $21.3 million for the same quarter in 2022.
  • S&M expenses were $13.7 million for the quarter ended September 30, 2023, compared to $16.8 million for the same quarter in 2022.
  • G&A expenses were $9.4 million for the quarter ended September 30, 2023, compared to $19.6 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

Retrieved on: 
Tuesday, November 7, 2023
NYSE, Calendar, NYSE Listed Company Manual

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
  • In accordance with Section 802.01C of the NYSE Listed Company Manual, the Company has a cure period of six months from receipt of the notice to regain compliance with the continued listing minimum price criteria.
  • The notice has no immediate impact on the listing of the Company’s common shares, which will remain listed and traded on the NYSE during this period, subject to the Company’s compliance with the other continued listing requirements.
  • The Company has notified the NYSE of its intent to cure the deficiency, which may include, if necessary, effecting a reverse share split, subject to board and shareholder approval.

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 6, 2023
ADC, Conference, Event, NYSE, Webcast, News, Broadcasting, Fine chemical

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT.
  • A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com.
  • A replay of the webcast will be available for approximately 30 days.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Poster, NYSE, 65th Berlin International Film Festival, Doctor of Philosophy, Research, AM, Society, ASH, San Diego Convention Center, Diffuse large B-cell lymphoma, ADC, Abstract, Rituximab, Therapy, Manchester Grand Hyatt Hotel, Patient, Pharmaceutical industry, MD

LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.
  • "We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • We look forward to additional details to be shared during the oral presentation.”
    Details of the oral presentation of the investigator-initiated study:
    Session: 623.
  • The abstracts are available through the ASH online meeting program.

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

Retrieved on: 
Tuesday, October 24, 2023
ADC, Therapy, NYSE, PIN, Clothing, Nursing, Pharmaceutical industry

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m.

Key Points: 
  • LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m.
  • ET to report financial results for the third quarter 2023 and provide business updates.
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

ADC Therapeutics to Participate in September Investor Conferences

Retrieved on: 
Tuesday, September 5, 2023
Webcast, ADC, Event, Conference, NYSE, Communications satellite

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.

Key Points: 
  • LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.
  • Details of the events are as follows:
    Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m.
  • ET
    Cantor Global Healthcare Conference - fireside chat on Wednesday, September 27th from 4:45 p.m. – 5:15 p.m.
  • ET
    Live webcasts of the fireside chats will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com.

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

Retrieved on: 
Thursday, August 31, 2023
Lymphoma, Loncastuximab tesirine, Abstract, Polatuzumab vedotin, Society, Progression-free survival, Follicular lymphoma, Diffuse large B-cell lymphoma, DLBCL, Safety, SOHO, Doctor of Philosophy, B-cell lymphoma, Nanakaly Hospital for Hematology & Oncology, Mosunetuzumab, Dor, The Year's Best Science Fiction: Eleventh Annual Collection, ADC, Poster, Trial of the century, Therapy, NYSE, ORR, Medical device, Pharmaceutical industry, Fine chemical, Rituximab, MD, Patient

LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023.

Key Points: 
  • For LOTIS-5, the Phase 3 study evaluating the combination of ZYNLONTA with rituximab, we are encouraged by the updated safety run-in results being presented at SOHO 2023.
  • It is the confirmatory trial for accelerated approval for 3L+ and would also support potential label expansion into 2L+ in combination with rituximab.
  • Dosing arms include ZYNLONTA (loncastuximab tesirine-lpyl) plus polatuzumab vedotin, as well as ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab and mosunetuzumab, t-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • Combining these agents with different mechanisms of action has the potential to have increased activity compared to either agent alone.

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 8, 2023
Mitsubishi Tanabe Pharma, Workforce, Biologics license application, Institutional review board, Rituximab, Medicare (United States), DLBCL, KAAG1, Infrastructure Investment and Jobs Act, IDMC, Medicare Part D, Overland, CD22, G&A, NSCLC, Lung cancer, EDT, Sale, IHC, Medicare, Sarcoma, PIN, Group purchasing organization, AXL, IRB, Patient, Investment, European, National Medical Products Administration, Immunohistochemistry, Growth, ADC, GPO, FDA, S&M, Therapy, MD Anderson Cancer Center, NYSE, BLA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, NMPA, Video game, Fine chemical, Pharmaceutical industry, Reinsurance, EU

LAUSANNE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter 2023 and provided business updates.

Key Points: 
  • We look forward to keeping you updated on our progress.”
    ZYNLONTA generated net sales of $19.2 million in the second quarter of 2023, representing an 11% increase over the second quarter of 2022.
  • The Company’s partner Sobi completed the first European commercial sale of ZYNLONTA with the launch in Germany in the second quarter of 2023.
  • R&D expenses were $31.9 million for the quarter ended June 30, 2023, compared to $48.5 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Retrieved on: 
Tuesday, August 1, 2023
ADC, PIN, Therapy, NYSE, EDT, Satellite navigation device, Nursing, Cryptocurrency

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.

Key Points: 
  • LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.
  • To access the conference call, please register here .
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A live webcast of the call will be available under the “Events and Presentations” tab in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .